# Requirements Package: Cross-Phase Clinical Intelligence Platform
**Date:** 2026-06-03  
**Based on:** Advanced AI Health Tech Market Analysis (2026-06-03)  
**Feature Opportunity:** Unified Clinical-to-Market Intelligence with Embedded AI Governance

---

## Feature Opportunity

### Identified Gap
No platform in the current competitive landscape bridges **pre-trial feasibility intelligence** (TrialHub), **payer/market access analytics** (MMIT), and **real-world patient voice signals** (Semalytix) into a single, continuous intelligence workspace. Simultaneously, all competitors lack native AI governance tooling—a rapidly escalating buyer requirement as regulatory scrutiny of "shadow AI" intensifies and the FDA expands its RWE framework.

### Proposed Feature Set
A **Cross-Phase Clinical Intelligence (CPCI) Module** that enables pharma R&D, clinical operations, and market access teams to track a single product or indication through the full lifecycle—from trial site selection through payer formulary adoption—with an embedded AI governance layer (audit logs, bias monitoring, explainability scores) available as a default, not an enterprise add-on.

---

## User Stories

### Story 1: Clinical Operations Strategist — Feasibility to Enrollment Handoff

**As a** clinical operations strategist at a mid-to-large pharmaceutical company,  
**I want** to see trial feasibility scores, site-level enrollment projections, and patient diversity signals on a single dashboard without switching between tools,  
**so that** I can make faster go/no-go decisions on site selection and proactively address enrollment diversity gaps before trial initiation.

#### Acceptance Criteria

**Scenario 1.1 — Dashboard loads cross-tool data**
- **Given** a user has linked their TrialHub-equivalent feasibility data and EHR-derived patient population data to the platform,
- **When** they open the Feasibility Dashboard for a specific indication,
- **Then** the system displays site scores, estimated enrollment velocity, and demographic coverage (by age, sex, race/ethnicity) in a single view within 5 seconds.

**Scenario 1.2 — Diversity gap alert**
- **Given** the platform has ingested real-world patient population benchmarks for the target indication,
- **When** projected site enrollment demographics fall more than 15% below benchmark representation for any demographic group,
- **Then** the system surfaces a flagged alert with suggested alternative sites that improve demographic coverage.

**Scenario 1.3 — No-data graceful degradation**
- **Given** a user selects a rare disease indication with fewer than 50 known trial sites globally,
- **When** the feasibility dashboard loads,
- **Then** the system clearly indicates data confidence levels per metric and does not suppress low-confidence data—it surfaces it with appropriate caveats.

---

### Story 2: Market Access Analyst — Payer Landscape Forecasting

**As a** market access analyst preparing a launch readiness dossier,  
**I want** to model formulary coverage scenarios for a pipeline asset using current payer policy data alongside competitive reimbursement benchmarks,  
**so that** I can forecast patient access rates by region before launch and identify where we need additional health economic evidence.

#### Acceptance Criteria

**Scenario 2.1 — Formulary scenario builder**
- **Given** the user inputs an ICD-10 indication and a drug class,
- **When** they run a coverage scenario model,
- **Then** the system returns projected formulary tier distribution across at least 50 major US payers, segmented by commercial, Medicare Part D, and Medicaid, within 10 seconds.

**Scenario 2.2 — Competitive benchmark overlay**
- **Given** the user selects two approved competitors in the same indication,
- **When** comparing formulary coverage,
- **Then** the platform displays a side-by-side coverage comparison including prior authorization requirements and step therapy restrictions, with data sourced from no more than 6 months ago.

**Scenario 2.3 — Evidence gap flagging**
- **Given** payer formulary data shows a coverage gap for a specific subpopulation (e.g., pediatric patients),
- **When** the user views the scenario results,
- **Then** the platform surfaces an evidence gap recommendation, linking to comparable RWE study types that have resolved similar coverage barriers in analogous cases.

---

### Story 3: Medical Affairs Lead — Patient Voice Integration

**As a** medical affairs lead developing a disease awareness strategy,  
**I want** to query aggregated, de-identified patient-reported outcomes and social health signals for my target indication,  
**so that** I can align our evidence generation strategy with unmet patient needs and communicate authentically with advocacy groups.

#### Acceptance Criteria

**Scenario 3.1 — Patient voice query**
- **Given** the user selects a therapeutic area and date range,
- **When** they submit a patient voice query,
- **Then** the system returns a ranked list of top 10 patient-reported themes (symptoms, treatment burden, quality-of-life concerns) drawn from verified public sources, with source attribution and volume metrics.

**Scenario 3.2 — Compliance guardrails**
- **Given** the system aggregates social health data,
- **When** any result set contains fewer than 50 unique source posts,
- **Then** the system suppresses the result and displays a privacy threshold notice, preventing inadvertent identification of rare-disease patient communities.

**Scenario 3.3 — Export for publication**
- **Given** a user wants to include patient voice data in a medical publication,
- **When** they export a dataset,
- **Then** the export includes a machine-readable data provenance report documenting source types, aggregation methodology, and de-identification approach, suitable for methods section disclosure.

---

### Story 4: Compliance Officer — AI Audit Trail

**As a** compliance officer at a pharma company deploying AI-generated insights in regulatory submissions,  
**I want** an immutable audit trail of every AI-generated insight, including model version, input parameters, and confidence scores,  
**so that** I can demonstrate to the FDA and EMA that AI-assisted decisions were traceable, explainable, and free of unmitigated bias.

#### Acceptance Criteria

**Scenario 4.1 — Automatic audit logging**
- **Given** any AI model generates an output used in a dashboard, report, or export,
- **When** that output is created,
- **Then** the system automatically records the model ID, version, timestamp, input parameters, output value, and confidence interval in an append-only audit log accessible to the compliance officer role.

**Scenario 4.2 — Bias monitoring report**
- **Given** the compliance officer requests a bias monitoring report for a given AI model over a 90-day period,
- **When** the report is generated,
- **Then** it includes performance disaggregation by demographic subgroup (age, sex, race/ethnicity where data is available), flagging any subgroup where model accuracy deviates more than 5% from overall accuracy.

**Scenario 4.3 — Audit export for regulatory submission**
- **Given** a compliance officer needs to submit an AI transparency dossier,
- **When** they export the audit trail for a specific product or project,
- **Then** the system produces a structured PDF and JSON export conforming to FDA's draft AI/ML Software as a Medical Device (SaMD) audit documentation guidelines.

---

### Story 5: Data Engineer — Federated Data Connectivity

**As a** data engineer at a health system partnering with a pharma sponsor,  
**I want** to connect our EHR data to the platform using federated queries that never require raw patient data to leave our firewall,  
**so that** we can contribute to clinical trial matching and RWE generation while remaining fully compliant with HIPAA and our institutional data governance policies.

#### Acceptance Criteria

**Scenario 5.1 — FHIR-native connector setup**
- **Given** the data engineer installs the platform's FHIR R4-compatible connector on their internal infrastructure,
- **When** they run a configuration test,
- **Then** the platform confirms connectivity and returns a data schema validation report within 2 minutes, with no patient-identifiable data transmitted externally.

**Scenario 5.2 — Federated query execution**
- **Given** a federated query is submitted by an authorized sponsor user,
- **When** the query executes across the health system's EHR,
- **Then** only aggregated, de-identified summary statistics (minimum cell size ≥ 10 patients per cohort) are returned to the platform; raw records remain on-premise.

**Scenario 5.3 — Data governance audit**
- **Given** the health system's IRB requires a log of all external queries run against their data,
- **When** the data engineer requests a query log,
- **Then** the platform provides a complete log of all queries executed, including submitting organization, query scope, timestamp, and result type, exportable in CSV and FHIR AuditEvent format.

---

## One-Page Product Spec

### Problem Statement
Pharmaceutical and MedTech teams operate with siloed intelligence tools: feasibility platforms know nothing about payer access dynamics; market access tools are disconnected from real-world patient experience; and AI-generated insights lack the governance infrastructure required for regulatory confidence. As a result, teams waste weeks reconciling outputs from disparate platforms, make go/no-go decisions with incomplete cross-phase visibility, and face increasing regulatory and reputational risk from ungoverned AI usage. The total addressable cost of this fragmentation is measurable: top-10 pharma companies report months of delay and multi-million dollar amendments attributable to information gaps between clinical and commercial teams.

### Proposed Solution
Build a **Cross-Phase Clinical Intelligence (CPCI) Module** that unifies feasibility intelligence, payer landscape analytics, patient voice insights, and AI governance tooling into a single authenticated workspace. Core architectural pillars:

1. **Federated data ingestion** — FHIR R4-native connectors enable health system participation without PHI transfer.
2. **Phase-linked intelligence graph** — Data objects (sites, indications, drugs, payers, patient cohorts) are linked across modules, allowing seamless pivot from trial to market view.
3. **Embedded AI governance** — Every AI output carries immutable metadata: model version, confidence score, demographic coverage, and bias flags.
4. **Configurable privacy thresholds** — Minimum cell sizes, data suppression rules, and export compliance controls are configurable per organization and jurisdiction.

### Success Metrics
| Metric | Baseline (Current) | Target (12 months post-launch) |
|---|---|---|
| Time to generate feasibility-to-market access brief | 3-6 weeks (manual reconciliation) | ≤ 3 business days |
| % of AI outputs with complete audit metadata | ~0% (no native tooling) | ≥ 95% |
| Health system data partnership activation | N/A | 5+ health system FHIR connectors live |
| Trial amendment rate attributable to site/enrollment gaps | Baseline TBD via client interviews | 20% reduction |
| NPS among Market Access Analysts (primary persona) | N/A | ≥ 45 |
| Customer AI governance incidents (shadow AI events) | Untracked | Tracked; YoY reduction target set at M6 |

### Out of Scope (v1.0)
- Direct EHR write-back or clinical workflow integration (e.g., order entry, clinical decision support at point of care)
- Consumer-facing patient portal or patient-direct mobile app
- Automated regulatory submission filing (audit trail export only; human review required)
- Real-time adverse event surveillance or pharmacovigilance automation
- Non-English language UI (planned for v1.1, Q4 2026)
- Integration with non-FHIR legacy HL7 v2 systems (separate roadmap item)

---

## Appendix: Research Basis

This requirements package is derived from the companion market analysis document (`market-analysis-2026-06-03.md`) and the following primary sources:

- [State of Health AI 2026 - Bessemer Venture Partners](https://www.bvp.com/atlas/state-of-health-ai-2026)
- [Agentic AI in Healthcare - BCG 2026](https://www.bcg.com/publications/2026/how-ai-agents-will-transform-health-care)
- [Life Sciences Software Market Gaps - IntuitionLabs](https://intuitionlabs.ai/articles/life-sciences-software-market-forecast-structural-gaps)
- [AI in Healthcare Trends - Wolters Kluwer 2026](https://www.wolterskluwer.com/en/expert-insights/2026-healthcare-ai-trends-insights-from-experts)
- [5 Emerging AI/ML Trends in Clinical Research - TechTarget](https://www.techtarget.com/pharmalifesciences/feature/5-emerging-AI-ML-trends-in-clinical-research)
- [Digital Health Transformation Gaps - HIMSS](https://www.himss.org/resources/digital-health-transformation-gains-gaps-and-the-growth-of-ai/)
- [AI in Healthcare Statistics 2026 - Uvik](https://uvik.net/blog/ai-in-healthcare-statistics-2026/)
